Note that as of 2023, injectable forms of GHK-Cu face regulatory restrictions for commercial compounding
Although there are currently no broadly effective specific treatments for LC, many are under investigation, and certain components have been effective for subsets of LC populations ( 10 , D-ribose for fatigue, anticoagulants and apheresis for abnormal clotting, Sulodexide and Pycnogenol for ED (128)
Some formulations contain additional substances such as L-carnitine or amino acids, which may interact with medications or underlying health conditions
The lack of information can leave potential users feeling uncertain about its safety
In some embodiments, the otic formulation or composition comprises about 25% by weight of the poloxamer
[Abstract]2024 Jun;269(Pt 2):131795